K-Ras^G12D Has a Potential Allosteric Small Molecule Binding Site

Area of Science:

• Oncology
• Molecular Biology
• Drug Discovery

Background:

• KRAS is a frequently mutated oncogene in various cancers, including pancreatic, colorectal, and lung cancers.
• Developing small molecule inhibitors for mutant KRAS proteins has been challenging.
• Targeting KRAS mutations presents a significant opportunity for cancer therapy.

Purpose of the Study:

• To identify and characterize a novel small molecule binding site on KRAS G12D.
• To discover and validate small molecules that bind to this site and inhibit KRAS G12D activity.
• To explore the therapeutic potential of targeting the identified KRAS G12D binding site.

Main Methods:

• Computational analyses were used to identify a putative small molecule binding site (P110) on KRAS G12D.
• A combination of computational and biochemical methods was employed to discover and validate small molecule binders.
• Techniques such as microscale thermophoresis, thermal shift assay, and nuclear magnetic resonance spectroscopy were used to confirm compound binding.

Main Results:

• A novel binding site, termed the P110 site, was identified on KRAS G12D.
• The small molecule KAL-21404358 was confirmed to bind specifically to the P110 site on KRAS G12D.
• KAL-21404358 demonstrated inhibition of KRAS G12D downstream signaling pathways, including RAF-MEK-ERK and PI3K-AKT.
• Development of more potent and soluble analogs based on the KAL-21404358 scaffold.

Conclusions:

• The P110 site represents a druggable target for KRAS G12D.
• Small molecule allosteric inhibitors targeting the P110 site hold promise for KRAS G12D-driven cancer treatment.
• Further development of KAL-21404358 analogs could lead to novel cancer therapeutics.